%0 Journal Article
%A Sparber-Sauer, Monika
%A Vokuhl, Christian
%A Seitz, Guido
%A Sorg, Benjamin
%A Tobias, Möllers
%A von Kalle, Thekla
%A Münter, Marc
%A Bielack, Stefan S
%A Ladenstein, Ruth
%A Ljungman, Gustaf
%A Niggli, Felix
%A Frühwald, Michael
%A Loff, Stefan
%A Klingebiel, Thomas
%A Koscielniak, Ewa
%T Infantile myofibromatosis: Excellent prognosis but also rare fatal progressive disease. Treatment results of five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry.
%J Pediatric blood & cancer
%V 69
%N 3
%@ 1545-5009
%C New York, NY
%I Wiley
%M DKFZ-2021-02243
%P e29403
%D 2022
%Z Volume69, Issue3, March 2022, e29403
%X Infantile myofibromatosis (IM) is a rare benign soft tissue tumor and often a self-limiting disease but rarely includes life-threatening complications. Little is known about optimal treatment of primary localized (LD) and multifocal disease (MFD).Treatment and outcome of 95 children with IM registered within five Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry (1981-2016) were evaluated.LD was diagnosed in 71 patients at a median age of 0.4 years (range 0.0-17.7). MFD was present in 24 patients. The mainstay of treatment was watch-and-wait strategy (w</td><td width="150">
%X w) after initial biopsy or resection. Low-dose chemotherapy (CHT) was administered to 16/71 (23
%K CWS Group (Other)
%K infantile myofibromatosis (Other)
%K infants and children (Other)
%K localized and multifocal disease (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34636137
%R 10.1002/pbc.29403
%U https://inrepo02.dkfz.de/record/177013